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Abstract: Growth Hormone (GH) may have many more effects on the human body
than those commonly known by the public. A study was conducted to determine
what these additional functions may be, if these functions could necessitate the
continued use of GH treatment for adults with Growth Hormone Deficiency (GHD),
and how these effects might invite the additional usage of GH as a treatment for
normal individuals. Research consisted of a literature review and a statistical
analysis of 86 adult GHD reports regarding how GH treatment had affected various
symptoms. Reports were analyzed for significance using one-way ANOVAs.
Observed results support that GH impacts energy, cognition, the cardiovascular
system, the integumentary system, thermoregulation, wound regeneration, and the
immune system. Each of these observed effects support that GH treatment may be
a requirement to maintain the health of adult GHD patients. Literature review results
also support that GH could be a possible treatment for cognitive impairment and
nervous tissue injury in normal individuals. Results also suggest that GH treatment
may not adequately attenuate hypohidrosis or poor thermoregulation symptoms in
GHD patients.
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Introduction:
Growth Hormone (GH) is an important hormone produced and secreted from
the pituitary gland. As its name suggests, it is most known for its role in the
elongation of bones from infancy until adulthood. GH is often prescribed to children
to treat known and idiopathic conditions that inhibit growth rates. The insistence on
this titular role being the only important mechanism caused by GH secretion has
been a majorly debated topic. Until the early aughts, most patients with GH
deficiency (GHD) stopped receiving treatment when they were fully grown. It had
been thought that there was no furthered need for the hormone supplementation as
again the titular role was thought to be the only role, and secretions of GH in healthy
adults were observed to decrease substantially. Hypersecretion of GH was also
observed to be detrimental to the body. In tandem, it had appeared that GH
treatment cessation for adults with GHD was the correct choice until these patients
were studied over an extended period.
The shared symptoms of these patients invited furthered research on GH. As
a hormone this molecule is secreted into the blood stream. It therefore is able to reach
the surface of most human cells. Most cells of the body also have receptors for growth
hormone (McKinley 674). These factors support that growth hormone could have
many more important functions in the body. The following thesis studies the health
and symptoms of 86 adult GHD patients and reviews the recent findings concerning
these many possible GH functions. The primary focus was to evaluate the continued
use of GH treatment for adult GHD patients and the possible use of GH to treat a
number of other diseases.
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Materials and Methods:
Literature collected for this study was found using the databases Proquest,
Science Direct, Elsevier, Clinical Skills, and Access Medicine. Gardner-Webb’s library
database includes these databases in its search, so it was prominently used. Standard
up to date undergraduate anatomy and cell biology textbooks were also used. All
articles obtained were in a digital format. The author of this review read and annotated
each article to truly understand the information held within each.
A survey was also conducted to evaluate whether patients’ symptoms align
with these recent literature findings. The survey follows current guidelines set by the
American Psychological Association concerning the ethical treatment of humans. CITI
training to conduct social and behavioral research was attained along with exempt
IRB research approval prior (i.e. file number 18100301) to the uploading of the survey.
The survey itself was created using the webtool Google Forms. It includes an informed
consent document to be read by participants before they begin the survey. A
debriefing statement is also included at the end of the survey for participants to read.
The survey was posted on the Magic Foundation Adult GHD and Panhypopituitarism
Facebook group. Members were invited to take the survey, but they could also scroll
past the post if they did not wish to participate. Subjects were only at minimal risk.
This is estimated based on the fact that individuals answered questions anonymously.
Each subject attained a random number before survey was taken. This was
accomplished by them clicking a link that redirects them to a random number
generator and then them pasting the resulting number to their second survey question.
No identifying factors were collected. Thus, not even the individual conducting the
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study was able to identify any of the participants. The study was also conducted online
which mitigates breaches of confidentiality by other subjects. Subjects were also
asked to skip questions they found to be too personal. This was to reduce any
emotional risks that may have arisen when someone took the survey. There are only
two questions that must be answered in the survey. The first asks participants to
confirm that they are 18 or older, have used GH treatment, have read the informed
consent document, and are aware that they can ask questions or drop out (i.e. by
emailing the researchers with their random number) at any time. The second forces
participants to copy/paste the previously mentioned random number. The remaining
questions concern the possible effects of GH and the demographics of the
participants. Questions are worded in a manner that does not lead individuals to select
specific answers. Results of the previously mentioned studies are also not specifically
mentioned in the survey. There were also a plethora of answer choices available for
each question. These factors allowed participants to answer in an honest manner.
They also remove possible skewing of the data due to patients being persuaded to
choose a particular answer choice. Demographics of the respondents can be found in
Table 1.
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Table 1: Demographics of Subjects That Participated in the Online Survey
Gender: n
Ethnicity:
Participants

n
Participants

Male
female

74
3
9

age:
18-23

24-29
30-39
40-49
50-59

60+

14
72

Caucasian
Asian
Other

n
cause of GHD:
Participants
6
Removal of
pituitary tumor
during childhood
3
Non-tumor derived
childhood onset
28
Congenital
panhypopituitarism
25
Congenital GHD
15
removal of pituitary
tumor during
adulthood
9
other

GH
treatment
duration:
t < 1 year
t > 1 year
t>2
years
t>5
years
t > 10
years

n Participants

12
7
30
12
25

n
Participants
3

9
6
3
26

39

The survey was analyzed using one-way ANOVAs which accessed the
significance of the variance between responses chosen for each question. ANOVAs
were created using the program Graphpad Prism. Each possible response was
designated as a single group. Groups included a set number of values corresponding
to the total number of individuals who answered the survey question. Values were
either 1 which signified that the participant had picked the response designated with
that group or 0 which signified that the designated response was not picked by that
participant. The one-way ANOVAs specifically analyzed variance among the resulting
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means of values in each group for a given question. Variance where calculated p
values were below 0.05 indicated that the prevalence of response choice was unlikely
to occur due to random chance. This result would imply that variance seen among
response groups is statistically significant. Once statistical significance was
determined, response choice prevalence was used to support or oppose literary
findings.
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Chapter 1: Growth Hormone’s Effects on Energy
One question asked in the survey conducted for this thesis was “Has GH
affected your level of energy?” The possible answers choices were: yes, I feel much
more invigorated than I used to; yes, I feel that I might have a bit more energy than I
used to; no, I notice no change in my average level of energy to perform tasks; Yes, I
feel more easily fatigued after beginning GH therapy; and Yes, my degree of fatigue
is so great that I find it difficult to get out of bed on most days of the week. The
percentage of responses chosen can be seen in Figure 20 (Appendix A). ANOVA
analysis (Figure 1) revealed that variance between selected answers was statistically
significant (p < 0.0001).

Figure 1. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 1 data. SI: strong increase; MI:
moderate increase; NC: no change; MD: moderate decline; SD: strong decline.
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Seventy six percent of those surveyed noticed improvement in their energy
level after starting GH therapy. Nearly 32% of those surveyed said that their energy
level had greatly increased. This subjective data supports that GH affects energy in
some manner. The reasoning behind these effects will be discussed.
Metabolism:
GH might regulate energy through its effects on metabolism. GH is known to
affect the storage and breakdown of lipids and proteins (Mckinley 674). Adenosine
triphosphate (ATP) is commonly referred to as the energy chemical as it is often used
to aid the occurrence of reactions in cells. These reactions must always be occurring,
or the cell will die. Thus, ATP is a necessary chemical. It can be made using
carbohydrates, lipids, and proteins. The storage and breakdown of these molecules is
thus incredibly important for survival. A 2009 study in the Journal Endocrine Reviews
mentions that GH may be the primary metabolic hormone while fasting.
Carbohydrates (e.g. glucose, fructose, lactose, and sucrose) are the primary
macromolecules used to make ATP in cells. When glucose is unavailable, the body is
able to use the building blocks of proteins and lipids to make ATP. GH is theorized to
be the primary metabolic actor during a fasting state because it has been observed to
be the only anabolic hormone that has an increased serum concentration during this
period. The scientists who wrote the previously mentioned 2009 study concluded from
a review of research on GH’s metabolic effects that GH increases lipolysis, decreases
lipogenesis, and inhibits protein breakdown during a fasting state. This conclusion was
supported by the fact that GH secretions during a fasting state caused serum
concentration of free fatty acids (i.e. the fragments of fatty tissue used for ATP
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production) to increase by 50%, caused a 50% reduction in urea production (i.e. a
process caused partly by a need to remove nitrogen from proteins to make ATP), and
caused a 50% reduction of protein breakdown in humans (Moller and Jorgensen 159161). Untreated GHD patients often exhibit abdominal weight gain. This symptom
appears to showcase an alteration in the metabolism of GHD patients. The increase
in weight is theorized to occur due to a decreased breakdown of fats and an increased
breakdown of lean muscle mass (Moller and Jorgensen 163). The body must use
either lipids or proteins to make ATP in fasting conditions. Lipids are preferred over
proteins because adipose tissue’s primary function is to store energy for later use.
Proteins have other uses, so they are often the last resort option to produce ATP in
normal patients. The increased abdominal weight and decreased muscle mass in
GHD patients seems to indicate that proteins from muscle are being used instead of
fats to make ATP in a fasting state. GHD patients thus have a 50% increase in protein
breakdown and a 50% decrease of lipid breakdown. Without GH, the body does not
properly utilize lipids to make ATP. Instead the body breaks down muscle tissue and
increases the amount of stored fats. This can cause the patient to feel fatigued due to
muscle breakdown and make them more susceptible to becoming obese. One 2002
study in the Journal of Clinical Endocrinology and Metabolism researched how three
years of GH treatment affected the body composition of 242 adult GHD patients. They
found that GH treatment resulted in a significant increase in lean body mass of most
GHD patients studied and a significant decrease in fat mass in the males with adult
onset GHD (Attanasio et al. 1604). This indicates that GH could attenuate the effects
of this abnormal usage of macromolecules seen in GHD patients. Thus, metabolism
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research on GH suggests that GH treatment may be a necessary treatment to regulate
the metabolism and energy level of GHD patients. Analysis of the survey conducted
for this thesis will further evaluate whether GH can reverse these symptoms of muscle
breakdown and weight gain due to lipid accumulation.
“Has your weight changed since you began GH therapy?” Available answer
choices were: yes, I have lost more than 45 pounds; Yes, I have lost more than 15
pounds; No, my weight has not changed by more than 15 pounds; Yes, I have gained
more than 15 pounds; and Yes, I have gained more than 45 pounds. The prevalence
of response chosen for this question can be found in Figure 21 (Appendix A). ANOVA
analysis (Figure 2) revealed that variance between selected answers was statistically
significant (p < 0.0001).
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Figure 2. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 2 data. L45: weight loss of more than
45 pounds; L15: weight loss between 15 and 44 pounds; NC: no major change; G15:
gained weight between 15 and 44 pounds; G45: weight gain of more than 45
pounds.
Nearly 13% of subjects said that they lost more than 45 pounds and 22.4% of
subjects said they had lost between 15 and 44 pounds. Forty percent of subjects
reported that their weight had not changed by more than 15 pounds. This large
percentage may indicate that GH’s effect of increasing lean muscle mass and
decreasing fat might result in no major in overall weight in some GHD patients. More
objective research is necessary to corroborate this hypothesis. The fact that 35.3%
subjects reported notable weight loss does support that GH has some effect on
metabolism.
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“Has your level of muscle mass been altered since you began GH therapy?” available
answers choices were: yes, I have more muscle mass and I have spent months trying
to increase my muscle mass; yes, I have more muscle mass, but my level of physical
activity would not warrant this increase; no, I have noticed no change in my muscle
mass; yes, I have less muscle mass than I used to, but I no longer exercise or lift
weights as much as I used to; and yes, I have less muscle mass than I used to and
my exercise regime has not changed. The prevalence of responses chosen for this
question can be found in Figure 22 (Appendix A). ANOVA analysis (Figure 3) revealed
that variance between selected answers was statistically significant (p < 0.0001).

Figure 3. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 3 data. MW: warranted muscle mass
increase; MUW: unwarranted muscle mass increase; NC: no change; LW: warranted
loss of muscle mass; LUW: unwarranted loss of muscle mass.
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This question was meant to evaluate whether GH treatment alone could
increase muscle mass in GHD patients. Nearly 33% of those surveyed said that their
muscle mass had increased after taking GH treatment even though they had not
performed any exercises that might elicit this effect. This muscle mass increase is
hypothesized to occur because their bodies have reduced the use of proteins to make
ATP. This result supports that GH regulates metabolism through its effects on protein
anabolism and catabolism.
Physical Capacity:
Endurance is another measurement of energy. GH might also affect an
individual’s ability to exercise. A 2008 metanalysis in the Journal of Clinical
Endocrinology and metabolism mentions that GHD patients often have reduced
physical endurance due to a decrease in muscle strength and a 27% decline in the
ability to properly utilize oxygen during exercise (i.e. measured via 𝑉𝑂2 max test)
(Widdowson and Gibney 4413). Fortunately, GH treatment appears to attenuate these
symptoms. The same 2008 metanalysis reviewed data collected from over 268 GHD
patients that received GH treatment. Their analysis revealed that GH treatment on
average caused maximal power output to increase by 40% and maximal oxygen
utilization to increase by 34% (Widdowson and Gibney 4415). These results support
that GH may be a necessary treatment for adult GHD patients to possess a healthy
capacity to exercise. It also suggests that GH might regulate energy level via its effects
on endurance.
The survey conducted for this thesis also gauged subject endurance. “Has your
physical endurance been altered by GH therapy?” The available answer choices were:
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yes, I find that I am able to handle exercising for 30-75 minutes more than I did
previously in one session; yes, I find that I am able to handle exercising for 10-25
minutes more than I did previously in one session; I notice no large difference in my
level of physical endurance; yes, I find that I must exercise for 10-25 minutes less than
my previous length of exercise in one session; and yes, I find that I must exercise for
30-75 minutes less than my previous length of exercise in one session. The
prevalence of responses chosen for this question can be found in Figure 23 (Appendix
A). ANOVA analysis (Figure 4) revealed that variance between selected answers was
statistically significant (p < 0.0001).

Figure 4. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 1 data. 30+I: 30 minutes or more
increase; 10+I: 10-25 minute increase; NC: no change; 10+d: 10-25 minute decline;
30+d: 30 minutes or more decline.
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Nearly 65% of those surveyed said that their exercise duration had increased
by 10 or more minutes since they began GH therapy. Twenty five percent of those
surveyed said that their exercise duration had increased by at least 25 minutes. These
results support that GH may increase endurance in GHD patients.
Mental Health:
What has been discussed thus far has been a possible explanation for how GH
might affect energy levels via its impact on both metabolism and endurance. Abnormal
mental health can also affect energy levels. Many GHD patients report having
depression, low Quality of Life (QOL), and anxiety when they are not on GH treatment.
GH might also regulate energy through its effects on mental health. Three studies on
this topic will be discussed.
A 2005 study in the Journal of Hormones and Behavior researched the effects
of GH therapy on memory and anxiety in GHD patients studied over a 10-year period.
They used the State-Trait Anxiety Inventory (STAI) to measure whether GH treatment
might reduce symptoms of anxiety. The STAI has resulting scores between 20 and 80
where a higher score indicates more severe anxiety symptoms. A significant decline
in scores from the baseline throughout the study indicated that, on average, GH
treatment did reduce symptoms of anxiety (i.e. p < 0.05). The average baseline score
was 35 and an average 6.4 point decrease was observed (Arwert et al. 347). This
supports that GH treatment may attenuate anxiety symptoms in GHD patients. Further
study on this topic should involve a larger sample size and the study of GHD patients
with much higher STAI scores to determine whether GH could greatly reduce
symptom severity in patients with more extreme anxiety.

Hutchins 16
If GH treatment can reduce anxiety in GHD patients, perhaps patients with
GHD may be at an increased risk of having a mental disorder. A 2018 study published
in the Journal of Growth Hormone and IGF Research evaluated whether children with
GHD might be at an increased risk of having a mental health condition. The study
reports that children with GHD may fail to mature psychologically, have a lack of selfconfidence, have poor social skills, and exhibit depressive symptoms. The objective
of the study was to investigate the relation between GHD, anxiety disorders, and
depression in youth. 122 minors with GHD and 122 healthy minors (i.e. aged 7–17)
were studied. 87 GHD patients received GH treatment and 35 did not. The Kiddie
Schedule for Affective Disorders and Schizophrenia for School-Age Children was
primarily used to evaluate whether subjects had a mental health condition. Additional
diagnosis tools were the DSM-V, the Children's Depression Inventory (CDI), the StateTrait Anxiety Inventory for Children (STAI-C), and the Social Anxiety Scale for
Children-Revised (SASC-R). Generalized Anxiety Disorder (GAD) and Social Anxiety
Disorder (SAD) were significantly more common in children with GHD compared to
the control group (i.e. there were 20 more diagnosed cases of GAD and 11 more
cases of SAD in GHD patients than in the control group). Depression diagnoses were
smaller in the GHD group, but this difference was not statistically significant (Akaltun
et al. 25-26). These results indicate that anxiety symptoms may appear more often in
untreated GHD patients. A similar analysis should be conducted on adults to
determine if this increased prevalence continues in adulthood.
Since such a study does not yet exist, the next best thing is a subjective 2014
study that asked 43 GHD patients (from either Germany, the United Kingdom, or the
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U.S.) to describe the effects of living without growth hormone. The researchers posit
that psychological impairment was most mentioned by the subjects (Brod et al. 4).
Prevalent symptoms were feelings of depression and anxiety. Subjects also said that
their condition caused them to be less socially active. GH treatment seemed to have
attenuated these symptoms (Brod et al. 6-7). It is unknown whether the improvements
reported by the subjects was merely a placebo effect. This study may lack substantial
evidence to back the claims of its subjects, but it does provide an idea of what some
adults with GHD could be experiencing. This data invites continued research on the
topic.
The survey conducted for this thesis also includes a question relating to mental
health. “Has GH therapy affected your mental state? Select all that apply” The
available answer choices were: yes, I once experienced anxiety, but I no longer
experience those symptoms; yes, I once experienced sad feelings for months at a
time, but those feelings have now ceased; no, I have a healthy mind and I have always
had a healthy mind; I am not sure, I did have anxiety or clinical depression before
starting GH treatment, but I take prescribed medications to attenuate those symptoms;
yes, I have had increased anxiety since I began GH treatment; and yes, I have felt
extreme sadness for a period lasting longer than a month since I began GH treatment.
The prevalence of responses chosen for this question can be found in Figure 24
(Appendix A). ANOVA analysis (Figure 5) revealed that variance between selected
answers was statistically significant (p < 0.0001).
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Figure 5. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 5 data. AA: attenuated anxiety; DA:
attenuated depression; N: never experienced symptoms; U: unsure; AW: anxiety
worsened; DW: depression worsened.
Thirty four percent of subjects said that their symptoms of clinical depression
had ceased after taking GH, but 6.2% admitted to having clinical depression
symptoms after starting GH. Twenty three percent reported a decrease in anxiety
symptoms and nearly 10% reported an increase in anxiety. GH dosage differences
among patients could account for this difference between patient reported
symptoms, but that is only a hypothesis. As previously mentioned, the questionnaire
had a very small sample size, so its results do not accurately reflect similar qualities
on the total population of adult GHD patients. It does however, invite further
investigation on how GH treatment may affect the mental health of adult GHD
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patients. The results do support that GH could attenuate depression and anxiety
symptoms in some GHD patients. Understanding if this is indeed the case with a
larger study and a possible investigation into the mechanism for how low GH causes
anxiety and depression will surely support furthered GH treatment use for adult GHD
patients.
Sleep:
Tiredness is an antonym of energy. GH might also be a necessary treatment
for adults with GHD because it regulates the secretion of Growth Hormone
Releasing Hormone (GHRH). It is important to mention that the Growth hormone
secretion pathway is regulated by a negative feedback mechanism. This mechanism
begins when the hypothalamus is stimulated to secrete GHRH. GHRH signals the
pituitary gland to secrete GH and then GH signals the liver to produce IGFs. When
serum concentrations of GH and IGFs become sufficient, both hormones will signal
the hypothalamus to stop secreting GHRH (McKinley 671-674). This mechanism is
brought to the forefront of discussion currently because the lack of regulation of this
pathway in GHD patients has been observed to disrupt sleep. A 2009 study in the
American Journal of Physiology researched how GHRH affected non-rapid eye
movement (NREM) sleep in rats. What they discovered was that GHRH injections in
the preoptic area of the hypothalamus significantly (p<0.001) increased NREM
durations and significantly (p<0.001) increased EEG slow wave activity during sleep.
They also found that GHRH antagonist hormone injections in the same area
exhibited an opposite effect (Peterfi et al. 149-150). This supports that GHRH
secretion levels heavily impact NREM sleep in mammals.
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GH directly inhibits GHRH secretion and GH is always secreted during the
initial 3rd and 4th stages of NREM in normal humans (qtd. in Peterfi et al. 147). These
two facts could also possibly explain why untreated GHD patients often feel fatigued.
Tiredness instead of physical or mental fatigue might contribute to this phenomenon.
A 2010 study in the Journal of Endocrinology and Metabolism researched
differences in reported tiredness, sleep stage durations, and EEG wave activity
during sleep among 30 normal individuals and 30 untreated GHD patients. Pituitary
specific (i.e. GH deficiency due to an inability of the pituitary gland to produce and
secrete GH) GHD patients were shown to have significantly increased durations of
NREM stages and significantly increased EEG slow wave activity compared to the
control group. The increases in these more objective values were also associated
with a high prevalence of reported poor sleep quality and tiredness during the day in
those patients (Copinschi et al. 2198-2201). This data supports that GHD patients
have altered sleep activity possibly due to a lack of GHRH secretion regulation by
GH.
The same group who conducted the 2010 human sleep study also published
a study in the European Journal of Endocrinology. This secondary study researched
whether 10 of those same pituitary specific GHD patients had improved sleep after
they were given GH treatment for 4 months. Differences in reported tiredness, sleep
stage durations, and EEG wave activity were similarly measured in this study. The
measurements attained from the 10 treated pituitary specific GHD patients were
compared with measurements taken from 10 saline treated pituitary specific patients
(i.e. which were also examined in the previous study). Seven participants had to
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leave the study. A significant decline in average total sleep duration and a significant
decline in EEG slow wave sleep activity were observed in the remaining GH treated
subjects. Sleep duration was, on average, an hour shorter in GH treated patients
than placebo treated patients (Morselli et al. 767-8). This difference in total sleep
duration was relevant because sleep duration is dependent upon the time it takes for
slow wave activity to reach minimum levels. GH treated patients also reported being
less tired. These researchers hypothesize from this resulting data that untreated
GHD patients exhibit increased tiredness and longer sleep times because the signal
to increase slow wave activity by GHRH is never turned off by GH. Thus, untreated
GHD patients could feel fatigued because their brains are still in a deep sleep
stimulating state.
The latter study has limited significance due to its small sample size. A
sample size of 13 subjects is not nearly enough to properly represent the total
population of GHD patients. The survey conducted for this thesis included questions
relating to sleep to possibly corroborate these claims with a larger sample size.
“Have you noticed a change in your ability to sleep since you began GH
therapy?” The available answers were: yes, once a week I will stay up for more than
24 hours because I cannot sleep; yes, biweekly I will stay up for more than 24 hours
because I cannot sleep; yes, once a month I will stay up for more than 24 hours
because I cannot sleep; yes, I often get less than 7 hours of sleep per night because
I toss and turn and am unable to fall asleep in an average amount of time; no, I
notice no change in my ability to sleep; yes, I find it much easier to fall asleep and I
often get 7 hours of sleep per night; yes, I find it incredibly easy to sleep and I often
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get 8-10 hours of sleep per night; and yes, I find that I sleep too much and yet I
never feel rested. The prevalence of responses chosen for this question can be
found in Figure 25 (Appendix A). ANOVA analysis (Figure 6) revealed that variance
between selected answers was statistically significant (p < 0.0001).

Figure 6. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 6 data. Weekly: one day without any
sleep weekly; biweekly: one day without any sleep biweekly; monthly: one day
without any sleep monthly; 7h>: often less than 7 hours; nc: no change; o7h: often 7
hours; o8-10h: often 8 to 10 hours; tms: too much sleep.
Nearly 40% of those surveyed reported that they can fall asleep easily and
that they often get healthy amounts of sleep each night. Only 4 individuals reported
that they sleep too often and yet never feel rested. These results support that GH
therapy may be able to improve sleep ability and sleep quality in GHD patients.
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Have you noticed any changes in your average sleep duration since you
began GH therapy? The available answer choices were: yes, I find that I often wake
up after an hour or 2 of being asleep; yes, I find that I often wake up after 3 to 4
hours of being asleep; no, I notice no changes in my average sleep duration; and
Yes, I find it extremely difficult to wake up after going to sleep. This question is
meant to gauge if GH therapy might reduce sleep time to such a degree that might
be detrimental to GHD patient health. The prevalence of responses chosen for this
question can be found in Figure 26 (Appendix A). ANOVA analysis (Figure 7)
revealed that variance between selected answers was statistically significant (p <
0.0001).
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Figure 7. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 7 data. 1-2 W: wake up after 1-2
hours; 3-4 W: wake up after 3 to 4 hours. NC: no change; IW: impaired waking
ability.
Fifty seven percent of those surveyed said they did not notice a change in
their average sleep duration. Twenty five percent of subjects said that they often
wake up after three or four hours. These results support that GH therapy could
cause some GHD patients to have unhealthy sleep durations. More research is
needed to determine if this might be a possible side effect.
Energy Conclusion:
GHD has been observed to reduce patient 𝑉𝑂2 max, physical strength,
endurance, lean body mass, and the serum concentration of free fatty acids. GHD
has also been observed to increase body fat and sleep duration. Patients with GHD
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also may have a higher incidence of anxiety and depression than the normal
population. These patients also report that they never feel well rested. Energy can
be affected by mental health, metabolism, endurance, and sleep. The discussed
survey results and the mentioned studies support that GH could regulate energy via
these four factors. Results also support that these symptoms can be attenuated via
GH treatment. It is surmised from this data that GH is a necessary treatment for
GHD patients because it appears to have a major effect on energy. These factors
alone indicate that GH treatment is integral to the health of adult GHD patients, but
there is much more to discuss to truly delineate why GH is a necessity.
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Chapter 2: Growth Hormone’s Effects on Cognition
The possibility of mental health effects caused by GH are just the tip of the
iceberg when it comes to the effects of GH on the brain. This section will examine
how GH might affect human cognition. Scientists define cognition as an animal’s
ability to process information (Nyberg and Hallberg 357). Processing information
could thus also be broken down into two sub categories: memory and intelligence.
Intelligence is the scale of one’s ability to understand a given topic in a certain
amount of time and memory is the ability to retain that understanding for a given
duration (Merriam-Webster.com). The definition of both concepts is generally
understood though the actual mechanism for their action is currently being
researched.
Memory:
Memory is easily quantifiable. One is either able to remember something or
unable to remember that thing. This binary mutually exclusive aspect of memory
makes it easy to detect changes in one’s ability to retain memories. Scientists have
not reached a consensus regarding how memories work though. The current theory
states that memories are unlike files in a computer. Memories are not stored in a
specific place nor are they an independent component of the brain. On the contrary,
memories are patterns of electrical signals among multiple synapses between
neurons (Nyberg and Hallberg 357-8). GH could regulate memory formation via its
effects on synaptic plasticity.
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Research on mice has shown that GH is able to stimulate synaptic plasticity
(i.e. the ability of synapses to alter their membrane potential) (Molina). This
stimulation of synaptic plasticity is said to activate long term potentiation (i.e.
prolonged transmission between two synapses based on previous electrical patterns
experienced by the neuron), which plays a role in learning and long-term memory
storage (Nyberg and Hallberg 357-8). Said stimulation is believed to be transmitted
via glutamate receptors. When bound to glutamate, these receptors signal calcium
and sodium channels to open which signal synaptic plasticity and an action potential.
GH is theorized to play a role in the formation of different subunits that make up the
glutamate receptor N-Methyl-D aspartate (NMDA). The theorized mechanism is
thought to involve the JAK-STAT pathway. The JAK-STAT pathway is a common
cellular signaling pathway that is often activated by cytokines. This pathway has
three components: a receptor on the surface of the cell that binds to ligands such as
cytokines or hormones, Janus kinases (i.e. a type of protein that adds a phosphate
group to another protein to activate that protein), and STATs (i.e. signal transducers
and activators of transcription). A signal cascade caused by the JAK-STAT pathway
involves a ligand binding to the receptor which signals Janus kinases to
phosphorylate the receptor using ATP. The newly phosphorylated receptor
phosphorylates STAT molecules. When STATS are activated through
phosphorylation, they form dimers and relocate to the nucleus where they will then
modify the transcription of genes which alters protein production in the cell. GH is
said to bind to its receptor GHR which signals Janus Kinases to phosphorylate the
receptor. This reaction causes the signal cascade mentioned above and causes

Hutchins 28
STAT dimers to then travel through the nucleus and bind to DNA to increase the
transcription of genes associated with the NMDA receptor (i.e. GluN1, GluN2A and
PSD‑95). GH is also theorized to stimulate the binding of glutamate to NMDA
(Nyberg and Hallberg 360-3).
GH may also play a role in synaptic plasticity through its effects on NF-kB
activation. NF-kB has been theorized to play a role in the transformation of a shortterm memory to a long-term memory (Kaltschmidt). One study showed that crabs
with inhibited NF-kB expression had significantly impaired ability to form long term
memories (Merlo). GH has not been proven to increase NF-kB activation in the
brain, but there is evidence that it stimulates NF-kB activation in other areas of the
body. Multiple studies have found that GH does regulate NF-KB activation in the
lungs, in adipose tissue, in macrophages, and other somatic cells (Liu, Jeay, and
Kumar). It is hypothesized that GH may also regulate memory formation via the
activation of NF-KB. Further research to test this hypothesis is needed, but the fact
that GH can activate NF-KB in other areas of the body and the fact NF-KB regulates
memory formation may indicate that there are more GH mechanisms that are
important to memory maintenance. GH thus may play a role in ensuring proper
memory formation in the mammalian brain via its ability to increase synaptic
plasticity by possibly regulating NMDA receptors and NF-KB secretions.
Intelligence:
Intelligence does not yet have a discernible marker in the brain. The
intelligence quotient is often used to determine one’s intelligence, but scientists are
not yet sure of what causes one person to be more intelligent than another
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individual. It is hypothesized that intelligence may have something to do with the glial
cells of the CNS. The primary example that can support this conclusion lies in a
1985 study on the genius, Albert Einstein’s brain. This study found that Albert
Einstein’s brain only differed from other lower IQ brains in that it had more glial cells
in a region of the brain that was believed to have a role in logic and mathematical
reasoning (Diamond et al. 201-4). The following paragraphs will detail how GH might
affect glial cells.
Scientists in Madrid, Spain discovered that GH may affect the development of
astrocytes. They studied hypothalamus and hippocampus astrocytes. In this study
they found that GH treatment on rat brains was found to increase the secretion of
GFAP (i.e. a protein secreted specifically by differentiated astrocytes). This indicates
that GH may cause immature astrocytes to differentiate. They theorized that GH
played a role in the successful differentiation of these cells through its binding to
plasma membrane GH receptors which signaled the activation of a PI3K/AKT
pathway. The PI3K/AKT pathway is a cellular signaling pathway that is often
activated by a growth factor ligand. Its signaling cascade involves a receptor tyrosine
kinase, a phosphatidylinositide 3 kinase (PI3K), phosphatidylinositol 4,5bisphosphate (PIP2), mTOR, pyruvate dehydrogenase kinase 1 (PDK1) and
Serine/Threonine protein kinase (AKT). The pathway begins as a growth factor (e.g.
growth hormone) binds to the cell surface portion of 2 receptor tyrosine kinases that
have dimerized. The receptor complex stimulates the autophosphorylation of the
cytoplasmic side of the receptor tyrosine kinases. PI3K then binds to the
phosphorylated tyrosine kinases. The receptor tyrosine kinase then phosphorylates
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PI3K which phosphorylates PIP2 (PIP2 becomes PIP3 which stands for
phosphatidylinositol 3,4,5-triphosphate). AKT then binds to PIP3 and is
phosphorylated by either a PIP3 bound PDK1 or an mTOR complex. Activated AKT
then may cause the cell to alter glucose metabolism, inhibit apoptosis (programmed
cell death), alter gene transcription, stimulate cell differentiation, signal cell
proliferation, alter GABA receptor expression, or activate NF-kB which has been
shown to play an important role in both synaptic plasticity and immune system
regulation. In summary, GH may cause astrocytes to differentiate through this
cellular pathway. Growth hormone releasing peptides were also shown to signal the
astrocytes to multiply in number through the same PI3K/AKT pathway. These
scientists corroborated their assumptions by preventing the ligand binding of GH and
GHRPs to their receptors on the astrocytes and found the side effects mentioned
above to be reversed. The same effect was observed when PI3k activation was
blocked (Baquedano et al. 266-272). This supports that GH and the peptides
associated with it, could play a role in the division and development of astrocytes.
Oligodendrocytes
A joint study between Wake Forrest University and University of Oklahoma
found that GH helps regulate the production and survival of oligodendrocytes.
Corpus callosum oligodendrocytes in rats with growth hormone deficiency were
researched. These scientists found that the GH deficiency inhibited the creation of
new cells. Two weeks after the cessation of GH treatment, the size of the newly
created group of immature oligodendrocytes had been 25% fewer than past
observed groups. GH deficiency was also found to inhibit the survival of new
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oligodendrocytes. The two effects led to a 30% decrease in the total population of
oligodendrocytes in the corpus callosum (Hua et al.1064-6). These results indicate
that GH stimulates the proliferation and successful survival of oligodendrocytes in
some manner. The scientists theorized that this drop in the oligodendrocyte
population (i.e. due to a decrease in GH and IGF-1) might be a cause of the
cognitive decline that occurs due to aging (Hua et al. 1068). GH secretion naturally
declines as one ages, and thus the possible reduction in these myelinating agents
would decrease the speed of signaling between neurons. This notion is supported by
another study which found that normal elderly patients with the best cognitive ability
out of those tested were shown to produce more GH than the other subjects (Quik et
al.). GH thus may influence intelligence through its role in regulating oligodendrocyte
proliferation and survival rate.
GH may regulate memory through its effects on synaptic plasticity, and GH
may affect intelligence by stimulating the proliferation and differentiation of glial cells.
What may be equally as important in discerning how GH affects cognition are
studies on the clinical manifestations of the absence of and use of GH treatment in
GHD patients in relation to cognitive functioning. The above list of possible
mechanisms for how GH might affect cognition are somewhat meaningless without
studies that examine whether cognitive function is even altered in GHD patients.
Clinical testing for changes in intelligence and memory will now be discussed in the
form of IQ and memory differences among GHD patients without GH treatment,
GHD patient that receive GH treatment, and healthy individuals.
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Clinical Manifestations:
A group of pediatric endocrinologists from the Netherlands endeavored to
study children treated with GH due to them being vertically challenged. They
endeavored to determine if GH had any additional functions besides increased
height. Fifty-three children took an Intelligence Quotient examination throughout an
8-year GH treatment period. IQ was shown to increase at a statistically significant
rate throughout the treatment with mean scores either coming close to or surpassing
the average scores of the general population (Chaplin et al. 395-8) These results are
promising, but more data is needed to truly determine if GH increases IQ in GHD
patients. IQ does change slightly during childhood, which could skew the data they
found. An adult study of the same nature is needed to truly determine if GH has the
ability to increase IQ.
Members of the Neuropsychology department at the University of Amsterdam
studied 30 GHD adults with an age range between 42 and 76. They tested the
adults’ working memory and learning ability. Low dose patients were found to have
deteriorated memory and learning ability at the end of the four-year session. High
dose patients had means higher than baseline in both aspects at the end of the fouryear session (Deijen et al. 4) This difference may be because entrance of GH past
the blood brain barrier is dependent on dosage (Nyberg and Hallberg 359). The
large age range and small survey size limit what can be concluded from the study
though.
The same group also studied 23 GHD adult men for a ten-year period. This
study was previously mentioned because it also researched mental health in GHD
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parents. These scientists also endeavored to learn about growth hormone’s effects
on mood memory in GHD patients. They found that the patients’ short term memory
began to improve after one year, while long term memory improved after two years.
Both memory types were found to improve for the first five years of treatment.
Memory tests were never similar, so patients could never prepare for said
examinations. The scientists were forced to reduce the GH dosage administered
during the final five years. The final tests at the end of the period showed memory
scores below the fifth-year scores, but above the baseline and all other test scores
(Arwert et al. 347). This result supports the previously mentioned dosage blood brain
barrier theory. The Survey size might be too low to be representative of GH’s effects
on all GHD patients, but these results support that GH could play a prominent role in
memory function.
A 2006 meta-analysis in the Journal of Psychoneuroendocrinology analyzed
multiple studies that tested memory impairment difference between untreated GHD
patients, treated GHD patients, and normal patients. Altogether the analysis studied
more than 300 patients. What they found was that untreated GHD patients had
much worse memory than those of the normal population. They also found that GH
treatment typically attenuated these symptoms. Moderate improvement of memory
was observed after 6 months of GH treatment, but the GHD treated patients were
never observed to have equal memory capacity with those of the normal patients
(Falleti et al. 685-9).
The survey conducted for this thesis also gauges the clinical manifestations of
cognitive impairment in GHD patients. This was done by asking patients about how
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they felt GH has affected their different cognitive abilities. “What is your highest level
of academic achievement?” Available answer choices were: Less than a high school
diploma, High school diploma, Some college, Associates, Bachelor’s, Master’s,
Doctorate, and Post Doctorate. This question was meant to gauge intelligence. An
IQ question would have been more quantitative, but it was doubtful that most
subjects would be aware of their IQ. Intelligence is all about learning ability and
those who learn better are more inclined to do well in their collegiate pursuits. The
prevalence of responses chosen for this question can be found in Figure 27
(Appendix B). ANOVA analysis (Figure 8) revealed that variance between selected
answers was statistically significant (p < 0.0001).

Figure 8. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 8 data. LHS: less than high school
diploma; HS: high school diploma; SC: some college; A: associates degree; B:
bachelor’s degree; M: master’s degree; D: doctorate; PD: post doctorate.
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A 2010 Harvard University and Asian Development Bank study found that
6.7% of the global population had a college degree of some kind (Barro and Lee 32).
The latest American census mentions that 33.4% of the American population has a
bachelor’s or higher degree (qtd. in Alonzo). Fifty seven percent of those surveyed
have college degrees of some kind. Forty three percent of respondents attained a
bachelor’s or higher degree. A limitation of this question is that it does not establish if
GH was taken during matriculation periods. The significance of these results is
inhibited by this limitation. The results somewhat support previous findings that GH
might increase intelligence. The next question delves further into how GH might
affect school performance.
“If you are a student, do you feel that growth hormone treatment has affected
your school performance?” Available answers choices were: yes, my grades have
improved slightly since I began GH treatment; yes, my grades have improved
significantly since I began GH treatment; I have witnessed no change in my
academic performance since taking growth hormone injections; yes, my grades have
declined slightly since I began GH treatment; and yes, my grades have declined
significantly since I began GH treatment. This question has much fewer responses
because only 30 of the 86 participants were currently in school. The significance of
the results is minimal due to the small sample size but they do invite further testing
regarding this topic. As was already discussed, GH seems to play a role in
regulating memory formation and intelligence. It would be difficult to argue that each
of these factors are not integral to getting good grades in school. Thus, the question
can be used to subjectively assess the quality of those factors. The prevalence of
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responses chosen for this question can be found in Figure 28 (Appendix B). 16
individuals reported no effect, 12 reported improvement, and 2 reported decline.
ANOVA analysis (Figure 9) revealed that variance between selected answers was
statistically significant (p < 0.0001).

Figure 9. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 9 data. N: no change; SI: strong
improvement; MI: moderate improvement; SD: strong decline; MD: moderate
decline.
Forty percent of those who responded say that their grades improved. These
results somewhat support that GH therapy can attenuate cognitive decline
symptoms in GHD patients. The next question focuses specifically on memory.
“Has GH treatment affected your memory?” Available answers choices were:
yes, GH has strengthened my short-term memory. I have an easier time memorizing
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phone numbers and other lists of 7-10 letters and numbers after a couple of minutes;
Yes, GH has strengthened my long-term memory. I have an easier time recalling
concepts or scheduled tasks that I have tried to memorize and remember for a
period lasting longer than 1 day; No, I have noticed no change in my ability to store
and retain memories following the inception of my growth hormone therapy; Yes, GH
has weakened my short-term memory. I find it difficult to memorize phone numbers
and other lists of 7-10 letters and numbers after a couple of minutes; and yes, GH
has weakened my long-term memory. I find it harder to recall concepts or scheduled
tasks that I have tried to memorize and remember for a period lasting longer than 1
day. The prevalence of responses chosen for this question can be found in Figure
29 (Appendix B). ANOVA analysis (Figure 10) revealed that variance between
selected answers was statistically significant (p < 0.0001).
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Figure 10. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 10 data. SST: strengthened shortterm memory; SLT: strengthened long-term memory; NC: no change; WST:
worsened short-term memory; WLT: worsened long-term memory.
More than 25% of those surveyed mention that GH has improved both their
short-term and long-term memory. Less than 6% mentioned that their ability to form
long-term and short-term memories had worsened after they started GH. Such a
discrepancy without any prompting of the subjects supports that GH treatment might
improve memory in GHD patients.
These discoveries on how GH effects cognitive ability in GHD patients have
incentivized some scientists to test if GH could enhance cognitive recovery in the
normal population. GH may also serve roles that directly affect neurons. Research
shows that GH acts as a neurotropic factor. Neurotropic factors are peptides that
stimulate the development and differentiation of neurons. These factors are also
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believed to increase the survival of neurons. Their method of action is through
tyrosine kinase (i.e. mostly receptor tyrosine kinases such as the one in the
previously mentioned PI3K/AKT pathway). Neurotropic factors were also observed
to stimulate the reparation of damaged neurons in vitro (Malenka 211-221). GH’s
use as a treatment for cognitive impairment in non-deficient patients is still being
researched though. At present there are a few case studies and some murine
experiments that indicate that GH can attenuate the symptoms of brain damage.
One murine study researched the use of growth hormone as a treatment to
attenuate cognitive impairment in stroke (i.e. a condition characterized by the death
of neural tissue due to a lack of blood flow to the affected area) induced mice. Mice
were given GH for 28 days 48 hours after the stroke was induced. GH-treated mice
had a better learning capacity over control groups. GH-treated mice were also
observed to have significantly less neural tissue death. Other neurotropic factor
populations were also raised in GH treated mice. Factors which indicate the creation
of new synapses (i.e. Synapsin-1) and the remyelination (i.e. Myelin basic protein) of
neurons were present in much higher numbers in the stroke affected tissue of GH
treated mice. CD31 and collagen-IV which indicate the presence of vascular tissue
were also higher in number and present in more areas of the stroke affected tissue
in GH treated mice (Ong et al. 1257-1266). In summary, these scientists found that
GH could be a potential treatment for stroke victims because it was observed to
promote cognitive and neuronal recovery.
A human case study found that GH treatment was able to repair nerve
damage in a 61-year old man (i.e. with a normal functioning pituitary gland) that
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abused opioids. They found that GH was able to reduce the apoptosis of neural
tissue and promote the regeneration of neurons in the patient (Rhodin et al. 760-3).
As a case study these results provide insight into how GH treatment could benefit
similar patients, but it does not indicate without a doubt that this same positive end
result would be seen in similar patients.
Another human case study observed the effects of GH treatment in addition
to neurorehabilitation techniques to improve the cognitive capabilities of a plane
crash victim. The 18-year-old male patient was treated fifteen months after the
incident and was observed to have a nearly destroyed right hemisphere. The man
had a severe case of traumatic brain injury. Growth hormone was chosen as a
treatment because it was previously shown to stimulate neurogenesis and
angiogenesis in rats and it did not seem to have the negative effects generally
associated with the use of other neurotropic factors. He received two years of
treatment with a dosage of 1mg per day. Before treatment, he was unable to walk or
speak. He was able to sign himself out of the hospital at the end of treatment. On a
five-point scale, the patient was shown to have a 3-point increase in speech ability
and a 4-point increase in mobility (Devesa et al. 30472-30480).
Another case study observed the effects of GH treatment accompanied by
typical neuro rehabilitative techniques on a cognitively impaired child. The subject
was a 10-year-old female who had acute perinatal asphyxia during her birth. The girl
had normal pituitary function but was treated with GH to possibly improve her
cognitive capabilities. She received a dosage of 0.5 mg per day for three months
and later 1.2 mg every three days. Her traditional neurorehabilitation involved
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occupational therapy, speech therapy, and auditive therapy. The study lasted 9
months. Following treatment, her IQ increased by 29 points. The research group
observed that she was at her grade level in most subjects after completing the
treatment (Devesa et al. 2-7).
Attention:
The above studies and survey results support that GH effects cognition and
may be an effective treatment to attenuate cognitive decline. What has yet to be
discussed is whether GH might affect abilities related to cognition. Untreated GHD
patients may also have trouble focusing. The previously mentioned 2006 metaanalysis also gauged improvements in attention after GHD patients started GH. Data
from more than 300 patients was analyzed. Attention capability was significantly
worse in untreated GHD patients than in the healthy patients. The measured factor
with largest discrepancy between the two groups was attention. The analysis also
found that GH treatment had led to moderate or large improvement (after 6-9
months) in the attention capabilities of GHD patients (Falleti et al. 685-9). These
results support that GH could regulate attention to some degree. The previously
mentioned 2018 article in the Journal of Growth Hormone and IGF Research
contradicts the meta-analysis findings though. It found no significant difference in the
prevalence of ADHD in minors with GHD (Akaltun et al. 25-26). This would support
that GHD does not cause ADHD.
Clinical manifestations of attention abnormalities in GHD patients yield
inconclusive results. It may be better to discern the effect of GH on attention by
looking at the mechanisms involved. A 2001 study found that attention can be
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modified via NMDA receptors (Turchi and Sarter 103-117). The importance of GH
regarding these receptors has already been discussed. It is possible that GH could
regulate attention through its effects on NMDA receptors. GH secretion might also
be altered by ADHD medication. A 2003 study in the Journal of Child and
Adolescent Psychopharmacology researched how the ADHD medication guanfacine
effects growth hormone secretion in children with ADHD. Eight children with ages
ranging between 8 and 10 were studied. Patients either had ADHD with reading
disabilities or only ADHD. Guanfacine treatment caused GH secretion amounts to
significantly increase for both groups. Those with only ADHD had even higher GH
secretions (Halperin et al. 287-291). The lower GH increase in patients with reading
disabilities might further support that inhibition of GH secretion may contribute to
cognitive abnormalities. The more novel result of the study is the fact that a
medication for ADHD somehow affects the mechanism for GH secretion. Such a
small sample size fails to represent the larger population of individuals with GHD,
but it does support that there could be a relationship between GH and attention. The
questionnaire attempts to further evaluate the clinical manifestations of these effects
on attention.
The prevalence of responses chosen for this question can be found in Figure
30 (Appendix B). 15 of the 86 subjects reported being diagnosed with ADHD. The
2018 study mentioned above found 7 of the 122 GHD patients and 6 of the 122
healthy patients to have ADHD. When compared to the 2018 study, the survey
responses support that there may be increased prevalence of ADHD in adults with
GHD. The smaller sample size limits one’s ability to discern whether this is true of
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the larger GHD population though. The next question gauges improvement of
attention in those surveyed.
Increased focus duration should be directly caused by improvement in
attention capability. The prevalence of responses chosen for this question can be
found in Figure 31 (Appendix B). Thirty-five individuals reported having improvement
in their ability to focus. Twelve of those 35 reported that their focus duration
improved by two hours. Forty-four noticed no change and 5 reported decline in focus
duration. ANOVA analysis (Figure 11) revealed that variance between selected
answers was statistically significant (p < 0.0001).
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Figure 11. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 12 data. 2I: 2 hour increase; 1I: 1 hour
increase; .5I: 30 minute increase; .25I: 15 minute increase; NC: no change; .5d: 30
minute decline; 1d: 1 hour decline; .25d: 15 minute decline; 2d: 2 hour decline.

It is possible that the effects noticed by these patients could have also been
caused by the placebo effect. The likelihood of this being the case was combatted
by the wording of the question. It was not asked if GH improved attention. Subjects
were only asked to describe if there were any changes in attention. The 35
individuals that said they had improved attention were not in any way prompted to
come to such a conclusion. The fact that 41.7% of subjects independently concluded
that their attention span improved after taking GH supports the validity that GH
affects attention in some manner.
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Cognition Conclusion:
In tandem, there exist possible mechanisms for how GH might effect
cognition; known examples of GHD patients without treatment being cognitively
impaired; known examples of GH treatment improving cognitive capacity in both
GHD patients and in patients with brain injuries; known examples of GH being used
to repair nervous tissue, known examples that GHD patients appear to struggle with
poor attention capabilities, and known examples that GH treatment can attenuate
those low attention symptoms. This plethora of data was supported by the
questionnaire responses. Growth hormone could be integral to nervous system
functioning. Not all is known about how GH secretion affects nervous tissue, but
available data does certainly provide just enough information to invite furthered
study. GH must hold some importance, or the previously mentioned effects would
not be reported. Evidence suggests that many GHD patients could exhibit cognitive
decline without treatment. It is supported by previously mentioned data that GH can
improve cognition in GHD patients. New research also suggests GH could be a
treatment to restore nervous tissue function and attenuate cognitive impairment in
normal patients. It could be argued that GH is more important for cognitive
functioning than it is for bone elongation.
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Chapter 3: Growth Hormone’s Effects on Other Bodily Functions
GH might also have effects on other organ systems. Most organ systems
contain cells with Growth Hormone Receptors (GHRs), so it possible that GH can
regulate more unmentioned mechanisms. GH’s possible effects on the
cardiovascular system, the integumentary system, thermoregulation, wound
regeneration, and the immune system will now be discussed.
Cardiovascular System:
Recent research supports that GH could affect cardiac structure and some
aspects of cardiovascular function. GH may affect blood pressure via its regulatory
effects on nerves. This is theorized because GHD patients have been observed to
have overactive sympathetic nerve signaling to vasculature smooth muscles. Such
an observation indicates that GH could lower blood pressure by decreasing
peripheral resistance. This is further supported by recent findings that show that this
symptom of overactive sympathetic nerve activity was observed to be attenuated
after one year of GH treatment (Isgaard et al. 26). While this mechanism for how GH
could affect blood pressure is credible, clinical manifestations of blood pressure
alteration due to GH are inconclusive. Some studies indicate that GHD patients had
hypertension that can be attenuated with GH treatment. Other studies found that GH
did not affect blood pressure (Isgaard et al. 26). This indicates that more research is
necessary to truly discern GH’s effects on blood pressure.
The effects of GH on heart structure and function appear to be more
conclusive. GHD patients without treatment were observed to have a smaller left
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ventricular mass and decreased cardiac output (Isgaard et al. 27). Cardiac output
was observed to be lower than normal patient control groups by an average of 17%
while resting and by 29% during exercise in GHD patients younger than 40. GH
treatment was observed to boost cardio-myocyte growth, improve systolic and
diastolic cardiac function, increase stroke volume, increase heart rate, and increase
left ventricular mass size (Isgaard et al. 28). Such observations support that GH may
be necessary to maintain healthy cardiac function. Untreated GHD patients were
also observed to have an average 40% increased risk of having a heart attack in a
study with sample size of 1411 GHD patients. Another study with a sample size of
289 GHD patients observed that those treated with GH were at a lower risk of having
a heart attack than normal patients (Isgaard et al. 29-30). Such observations support
that GH may be necessary to maintain healthy cardiac function.
The survey conducted for this thesis also includes questions relating to the
cardiovascular system. The first question asked patients to detail if they had a heart
condition. Have you been diagnosed with any heart abnormalities? Available answer
choices were: yes, I have some heart abnormalities and I was diagnosed with such
conditions after being diagnosed with GHD; yes, I have some heart abnormalities
and I was diagnosed with such conditions before being diagnosed with GHD; and I
do not have any diagnosed heart abnormalities. The prevalence of responses
chosen for this question can be found in Figure 32 (Appendix C). ANOVA analysis
(Figure 12) revealed that variance between selected answers was statistically
significant (p < 0.0001).
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Figure 12. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 13 data. HA: have acquired after;
HB: have acquired before; NHC: no known heart condition.
Eighty seven percent of those surveyed reported that they did not have any
diagnosed heart abnormality. This result opposes that GHD patients have altered
cardiac structure that contributes to major cardiac dysfunction.
The second cardiovascular question gauged how GH treatment affects
cardiovascular vital signs. Has your heart rate or blood pressure changed
significantly since you began GH therapy? Subjects were asked to select all answers
that applied to their current condition. Available answer choices were: yes, my
resting heart rate has increased by more than 20 beats per minute; yes, my systolic
and diastolic blood pressure are both 20 mm Hg higher than they were before I
began GH therapy; yes, I now have hypertension; no, there has been no change in
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my heart rate; no, there has been no change in my blood pressure; yes, my resting
heart rate has decreased by more than 15 beats per minute; yes, my systolic and
diastolic blood pressure are both 20 mm Hg lower than they were before I began GH
therapy; and yes, I now have hypotension. The prevalence of responses chosen for
this question can be found in Figure 33 (Appendix C). ANOVA analysis (Figure 13)
revealed that variance between selected answers was statistically significant (p <
0.0001).

Figure 13. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 14 data. IH: increased heart rate;
IBP: increased blood pressure; HYT: hypertension; NC HR: no change in heart rate;
NC BP: no change in blood pressure; DH: decreased heart rate; DBP: decreased
blood pressure; HOT; hypotension.
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More than 50% of those surveyed said that GH treatment did not affect their
blood pressure or heart rate. No other response choices were chosen by more than
10% of the subjects. These results do not oppose or support if GH effects
cardiovascular vital signs.
Skin:
Recent findings suggest that GH also regulates integumentary system
functions. A 2016 article in the Journal of Reviews in Endocrine and Metabolic
Disorders that focused on this on topic will be discussed. The researchers examined
how both hyper secretion (acromegaly) and hypo secretion (GHD) of GH affected
skin health. Acromegaly patients are observed to have hyperhidrosis (i.e. excess
sweat secretion), thick skin, skin roughness, the appearance of skin growths known
as acrochordons, and excessive oil secretions by sebaceous glands (Gantenbein et
al. 261). GHD patients often have hypohidrosis (i.e. diminished or a complete
absence of sweat secretions) and skin that is thin and dry (Gantenbein et al. 264).
The scientists responsible for this review mention that this near ubiquitous
appearance of these symptoms in patients with altered GH secretion could be used
in the future to diagnose both conditions (Gantenbein et al. 265). This apparent high
prevalence of symptoms suggests GH regulates the integumentary system in some
way. Furthered corroboration of this notion is the fact that nearly all integumentary
cells possess GH receptors (Gantenbein et al. 259).
The survey conducted for this thesis also includes questions relating to the
integumentary system. The first asked “Have you noticed any changes in your skin
since you began GH therapy?” The available answer choices were: yes, I have
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noticed a thinning of my skin since I began GH therapy; yes, I have noticed an
increase in the dryness of my skin since I began GH therapy; yes, I have noticed an
increase in the elasticity of my skin since I began GH therapy; no, I have noticed no
changes in my skin; yes, I have noticed a thickening of my skin since I began GH
therapy; yes, I have noticed a decrease in the dryness of my skin since I began GH
therapy; and yes, I have noticed a decrease in the elasticity of my skin since I began
GH therapy The prevalence of responses chosen for this question can be found in
Figure 34 (Appendix C). ANOVA analysis (Figure 14) revealed that variance
between selected answers was statistically significant (p < 0.0001).

Figure 14. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 15 data. Thin: thin skin apparent; ID:
increased dryness apparent; NC: no change; Thick: thick skin apparent; DD:
decreased dryness; DE: decreased elasticity.
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Fifty six percent of patients reported no noticeable change in their skin since
they began GH therapy. Reports of increased skin thickness and dryness were
roughly equal to reports decreased thickness and dryness. This data may indicate
that current GH treatment may be ineffective at reducing symptoms of thin and dry
skin. More research is needed to determine if this is true.
The second question focuses on sweat. “Has your ability to sweat been
affected by your growth hormone treatment?” The available answer choices were:
yes, I sweat a lot more now that I administer GH injections; yes, I sweat a lot less
now that I administer GH injections; no, I have noticed no change in my perspiration
rates since I began Growth Hormone treatment; and I am unsure because I have not
thought about my rate of perspiration until now. The prevalence of responses
chosen for this question can be found in Figure 35 (Appendix C). ANOVA analysis
(Figure 15) revealed that variance between selected answers was statistically
significant (p < 0.0001).

Hutchins 53

Figure 15. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 16 data. IS: increased sweating; DS:
decreased sweating; NC: no change; UK: unknown.
Twenty five percent of subjects said that GH therapy has caused them to
sweat much more than they used to. This result supports that GH therapy might
increase sweating ability in some GHD patients.
The importance of skin health may not be as well-known as that of cognitive
and heart health. It should be mentioned that the integumentary system is the first
line of defense against harmful agents (e.g. chemical toxins and pathogens) and a
regulator of body temperature. Aspects of the skin such as thickness and oil
lubrication are integral to the prevention of harmful agents entering the body. Sweat
secretion benefits temperature regulation. Merocrine glands are the exocrine glands
that secrete sweat which is 99% water and 1% electrolytes. To properly illustrate
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sweat’s importance, its role in attenuating temperature increase during exercise will
be described. Muscles release excess heat during exercise because they are
working harder and using more energy. Excess heat causes blood temperature to
increase. Peripheral blood vessels will dilate to transfer heat to the skin surface.
Heat does not easily escape through the skin to the atmosphere without another
participating molecule. This molecule is the water from the sweat. Merocrine glands
will begin to secrete sweat when body temperature increases. The heat is then
transferred from the skin to the sweat. This causes a lot of the sweat to evaporate.
Evaporation of sweat allows heat to be more easily removed from the body. Thus,
sweat is integral to proper thermoregulation in humans. The role of GH in regulating
the skin is important to the overall health of an individual
Thermoregulation:
The fact that GH deficiency causes hypohidrosis may indicate that GHD
patients are at an increased risk of hyperthermia. In 1995, Researchers from the
University of Copenhagen performed a controlled study on sweating and body
temperature regulation during exercise in the heat. Sixteen GH-treated GHD patients
and 10 healthy subjects were studied. Each subject exercised on a bicycle
ergometer for 60 minutes at a workload corresponding to 45% of their individual
maximal oxygen consumption (𝑉𝑂2 max), in a room maintained at 35C°. GH serum
concentrations increased significantly after approximately 10 min of exercise in the
normal subjects (P < 0.001) but remained low in the GHD patients. Skin temperature
increased significantly during exercise in the GHD patients but remained unaltered in
the healthy subjects (Hjortskov et al. 3337-8).
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These results support that GH-deficient patients may be at risk for developing
hyperthermia during physical activity in hot environments. It also indicates that the
traditional GH treatment of one injection every evening may not truly attenuate all of
the symptoms of GH deficiency.
A more recent study concerning the same topic was published in 2014. In it,
researchers recorded the variance of water loss, blood plasma volume, and blood
serum HGH in 8 highly trained triathlon athletes between resting and high impact
exercise states. All subjects had normal functioning pituitary glands. The athletes
were subjected to 2 exercise tests consisting of 20 minutes of running and 20
minutes of cycling separated by a break period of 30 seconds. The exercise
environment was such that each participant was performing at a level where their
bodies were consuming oxygen at rate that was 75% of its maximal value. Subjects
were divided randomly to either do cycling then running or running then cycling.
These individuals then returned after two weeks to perform the test in reverse order
of what they had done previously. Water loss was estimated by weighing the
subjects before and after each trial. Plasma volume and GH serum level were
recorded at rest and after each phase of a trial. The importance of cycling and
running was to test the researchers own hypothesis. They hypothesized that GH
secretion might be inhibited during exercise by baroreceptors and a known
baroreceptor reflex involved the quick transition from the angle the body is at while
cycling and the angle the body is at when running (Galy et al. 1). Plasma volume
and water loss were recorded to observe how the alteration of GH secretion might
affect sweat regulation. Measurement of water loss indicated the degree of sweat
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produced throughout a trial. Measurement of plasma volume is used in addition to
water loss detection because sweating causes merocrine glands to increase plasma
filtration which decreases plasma volume. Therefore, increased sweating was
detected via decreased plasma volume and decreased sweating was detected via
increased plasma volume. Average water loss was significantly lower in the
cycling1st-running2nd (C1R2) trial than the water loss amount after the running1stcycling2nd (R1C2) trial. A significant negative correlation was also observed
between plasma volume and serum HGH levels. As HGH increased in the blood,
plasma volume decreased further and further from the resting baseline. Perhaps the
most notable observation was that the C1-R2 trial (i.e. which was designed to elicit
the baroreceptor reflex) had a significantly lower serum HGH concentration at the
end of R2 than the HGH concentrations recorded for C2. R2 plasma volume was
also above resting baseline. C1, C2, and R1 plasma volumes were all lower than the
resting baseline (Galy et al. 4-5). This indicates that the reflex significantly inhibited
sweat secretion. In tandem, the results of the experiment support the researchers’
initial hypothesis that baroreceptors inhibit GH secretion during exercise. The results
also further support that GH increases sweating during exercise.
The results of these studies support that GH regulates thermoregulation
through its effects on the integumentary system. Baroreceptors seem to inhibit this
response, but the full mechanism for how GH elicits these effects is not yet known.
What is known is that the hypothalamus regulates body temperature and secretes
GHRH to stimulate the secretion of GH. Merocrine glands also have GH receptors
(10 of triathlon study). These correlations could allude to a possible pathway for how
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GH regulates sweating. The hypothalamus might receive signals that indicate that
body temperature is increasing and react to those signals by increasing GH
secretion via GHRH in order to stimulate merocrine glands to secrete more sweat.
More research is needed to determine if this possible pathway is true.
The survey conducted for this thesis also has a question relating to
thermoregulation. “Has your sensitivity to heat exposure been altered by GH
therapy?” The available answer choices were: yes, I feel that I am more susceptible
to heat stroke after beginning GH treatment; yes, I feel that I am less likely to
succumb to heat stroke after beginning GH treatment; no, I notice no change in my
heat sensitivity; and no, I am not heat sensitive and I have never had a sensitivity to
the heat. The prevalence of responses chosen for this question can be found in
Figure 36 (Appendix C). ANOVA analysis (Figure 16) revealed that variance
between selected answers was statistically significant (p < 0.0001).
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Figure 16. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 17 data. ISH: increased sensitivity to
heat; DSH: decreased sensitivity to heat; NC: no change; NP: Never experienced a
problem with heat sensitivity.
Six percent of those surveyed reported that they never were heat sensitive.
This indicates that 94% of those surveyed are heat sensitive. This result supports
that GHD patients may be at an increased risk of hyperthermia. Nearly 55% of those
surveyed said that GH therapy did not affect their heat tolerance. Twenty five
percent of those surveyed reported having decreased heat tolerance since they
started GH therapy. These results support that current GH treatment measures may
not attenuate heat sensitivity in all GHD patients.
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Regenerative Effects:
GH may also elicit additional proliferative and recovery effects during injury or
sickness. The first of these studies on wound recovery involves the role of GH as a
neurotropic factor. One treatment that may allow deaf patients to hear is known as a
cochlear implant. These implantations are only successful if deaf patients have
normally functioning spiral ganglion neurons. Recent studies indicate that
neurotropic factors may be able to repair degenerative damage to spiral ganglion
neurons in patients with hearing loss. GH stimulates neurite growth and neuronal
branching in other neuron types, so it might also exhibit these effects on spiral
ganglion neurons. A research group in Frankfurt, Germany attempted to evaluate
whether GH is a possible treatment to reverse spiral ganglion degeneration. They
examined the effects of GH on the inner ear spiral ganglia from mice. This
experiment was conducted in vitro. They observed significant neurite growth in the
petri dish ganglia which supports that GH could be a possible neuro regenerative
treatment to enable the use of cochlear implants (Gabrielpillai et al. 638-642).
Peripheral nerves are able to spontaneously recover without treatment, but
when regenerated in this manner, they lose a good proportion of their functional
capabilities. This dilemma has caused scientists to search for treatments that
improve nerve regeneration. A research group from the University of Santiago de
Compostela attempted to evaluate if GH treatment could be the solution physicians
have been searching for. A transection was performed on the left sciatic nerve of
studied adult rats. Transected rats were then either treated with GH or saline for a
period of 8 weeks. GH treated rats were observed to have more responsive axons
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and more Schwann cells than the saline treated rats. GH treated rats also performed
better in treadmill tests than did the saline rats (Devesa et al. 385-91). These results
support that GH could be a possible treatment to induce peripheral nerve
regeneration.
Growth hormone may also be able to accelerate and improve wound healing
in other types of tissue. Some believe that this effect may be caused by GH
stimulating the wound area to produce more IGF-1. One study published in the
journal Wounds discussed the effects of GH on wounded pigs. Pigs were given
either GH (2.5 IU/L applied to topically to the wound) or saline every other day.
Eleven applications (i.e. for each pig) of the saline or GH were given overall. Weekly
biopsies were used to evaluate the rate of wound healing in the pigs. Wounds were
observed to consistently heal faster in the GH-treated group than the control group
(p < 0.05). GH-treated pigs also had more collagen 1 and IGF-1 produced than
saline pigs (Kim et al. 159-161). These results support that GH may expedite wound
healing. Further research is necessary to determine if GH has similar effects in
humans though.
GH does regulate bone elongation. Could these effects and the above wound
healing data indicate that GH treatment might accelerate bone repair as well? A
study done in 2007 investigated this very subject. Researchers measured how GH
treatment affected the duration of time required to repair different types of tibia
fractures. Four hundred and six human patients (93 females and 313 males with
ages ranging between 18 and 34) were examined in this double-blind study.
Subjects had either an open or closed tibial fracture. Each patient was randomly
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assigned to either receive saline or growth hormone (15, 30, or 60 mg/kg daily
depending on the subgroup). Treatment ceased after full recovery was observed or
after 16 weeks of continuous treatment. Patients were observed every 4 weeks until
24 weeks had passed. Post assessment was also conducted 9 months and 12
months after the treatment began. There was no significant difference in open
fracture healing time between the control and the GH treated patients. GH treatment
for closed fracture patients yielded drastically different results. The subgroup treated
with 60 mg/kg of GH daily had an average 26% decrease in recovery time over the
control group (Raschke et al. 343-349). Why there is such a stark contrast for
effectiveness of GH between both fracture types is still unknown. Regardless, the
data does support that GH treatment could reduce healing time for closed fractures.
The survey conducted for this thesis also asked GHD patients to describe
their wound healing rate. “What is the average duration of time that you have spent
out of work or school due to an injury?” The available answer choices for this
question were: I typically stay out of work/school for more than one month; I typically
stay out of work/school for about one month; I typically stay out of work/school for
about 3 weeks; I typically stay out of work/school for about 2 weeks; I typically stay
out of work/school for about 10-13 days; I typically stay out of work/school for about
7-9 days; I typically stay out of work/school for about 4-6 days; and I typically stay
out of work/school for about 1-3 days. The prevalence of responses chosen for this
question can be found in Figure 37 (Appendix C). ANOVA analysis (Figure 17)
revealed that variance between selected answers was statistically significant (p <
0.0001).
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Figure 17. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 18 data. M+: stayed out for more
than a month, M: stayed out for a month; 3W: stayed out for 3 weeks; 2W: stayed
out for 2 weeks; 10-13D: stayed out for 10-13 days; 7-9D: stayed out for 7-9 days; 46D: stayed out for 4-6 days; 1-3D: stayed out for 1-3 days.
Fifty five percent of those surveyed said that they stayed out for 1 to 3 days.
This result could support that GH boosts wound regeneration rates, but more
research is needed to truly determine a cause and effect. This data might have more
validity if it were to be compared with that of a control group which was asked the
same question.
Immune System:
GH’s effects on the immune system will now be discussed. A 2009 study
reviewed how GH and Ghrelin affect the immune system. These hormones have
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been observed to interact with T lymphocytes, B lymphocytes, monocytes and
neutrophils. Each of these cells also contain GHRs and Growth Hormone
Secretagogue Receptors (GHS-Rs). Ghrelin appears to cause a signal cascade
when it interacts with GHS-R. This may indicate that Ghrelin plays an important role
in the regulation of the hypothalamic-pituitary axis. The conservative nature of cells
signifies that all molecules produced by a cell are also used by the cell in some way.
Thus, the sheer fact that these immune cells possess GHRs and GHS-Rs
corroborates the claim that Ghrelin and GH have a role in regulating the immune
system. This study reports that GH is responsible for “enhancing thymopoiesis and T
cell development, modulating cytokine production, enhancing B cell development
and antibody production, priming neutrophils and monocytes for superoxide anion
secretion, enhancing neutrophil adhesion and monocyte migration and anti-apoptotic
action” (Hattori 347). Ghrelin plays a role in the reduction of inflammation, the
regulation of thymopoiesis, the reduction of sepsis, and the regulation of
phagocytosis. It remains to be known whether the effects of Ghrelin are elicited by
GH or if the GH effects are elicited by IGF-1.
Results from other studies further support that GH affects the innate immune
system. A 2019 cancer cachexia study in the Journal PloS One observed that GH
activates and stimulates the proliferation of NK cells in cancer induced rats (Wei et
al. 6-7). Another study done in 2013 found that in vivo GH treatment of peritoneal
macrophages had caused these cells to be more phagocytic than the control (Reis
et al. 1). A 2004 review in the Journal of Pediatric Endocrine Reviews compiled a list
of other innate immune system effects. It mentions that GH was observed to
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stimulate the proliferation and differentiation of myeloid progenitor cells, that GH
stimulated monocyte chemotaxis and migration, and also caused monocytes;
macrophages; and neutrophils to increase production of phagocytic chemicals (i.e.
superoxide anions and hydrogen peroxide for monocytes) (Meazza et al. 5-6).
These studies support that GH could affect leukocyte regulation. They also
suggest that HGH could be used to boost immune function. There were also
questions in the survey conducted for this thesis that asked GHD patients to
describe how GH therapy effected their immune system. “Has your rate of
contracting an illness changed since you began GH therapy?” The available answer
choices were: yes, I have noticed that I have contracted 4 or more illnesses on
average than I did before I began GH treatment; yes, I have noticed that I have
contracted 2 to 3 more illnesses on average than I did before I began GH treatment;
no, I have noticed no change in my rate of contracting illnesses; yes, I have noticed
that I catch 2 to 3 fewer illnesses on average that I did before I began GH treatment;
and yes, I have noticed a major change in my health to such a degree that I now
typically only contract 1 to 2 illnesses a year. This question is designed to measure
the strength of the innate immune system within the subjects. Contracting fewer
illnesses would indicate that the physical barriers and innate immune system
leukocytes are strong enough to prevent more pathogens from multiplying to the
degree which would cause the subject to develop symptoms. GH seems to boost the
protective function of the skin and stimulate innate immune cells such as nk cells, so
it is possible that GH could enhance the innate immune system and reduce the
overall number of contracted illnesses. The prevalence of responses chosen for this
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question can be found in Figure 38 (Appendix C). ANOVA analysis (Figure 18)
revealed that variance between selected answers was statistically significant (p <
0.0001).

Figure 18. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 19 data. 4+: additional 4 or more
contracted illnesses per year; 2-3+: additional 2 to 3 more contracted illnesses per
year; NC: no change; 2-3-: decrease of 2 to 3 contracted illnesses per year; 1-2Y: 1
to 2 contracted illnesses per year.
Fifty seven percent of those surveyed report that they noticed no change.
Fifteen percent noticed they had contracted 2-3 fewer illnesses. Another 15%
reported that GH therapy vastly improved their innate immune function to a degree
where they now only get sick once or twice a year. The high prevalence of no
noticeable change may be because individuals do not often think of how many
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illnesses they contract in a year, but this is only a hypothesis. These results support
that GH could improve inmate immune system function in some GHD patients.
“Has the duration of an illness changed since you began GH therapy?” The
answer choices for this question were: yes, I noticed that a sickness duration is on
average a week or more longer than it would have been before I began GH
treatment; yes, I noticed that a sickness duration is on average 4-6 days longer than
it would have been before I began GH treatment; yes, I noticed that a sickness
duration is on average 1-3 days longer than it would have been before I began GH
treatment; I have noticed no change in the average length of sickness following the
contraction of a pathogen; yes, I noticed that a sickness duration is on average 1-3
days shorter than it would have been before I began GH treatment; yes, I noticed
that a sickness duration is on average 4-6 days shorter than it would have been
before I began GH treatment and yes, I noticed that a sickness duration is on
average 7-10 days shorter than it would have been before I began GH treatment.
This question is meant to assess whether GH treatment may cause the adaptive
immune response (i.e. activation and proliferation of B and T lymphocytes) to occur
at an earlier point than when the response occurred while these patients did not
receive GH treatment. Said alteration of response time would shorten the duration of
sickness in the patients. Thus, the overall duration is gauged to assess adaptive
immune response time. The prevalence of responses chosen for this question can
be found in Figure 39 (Appendix C). ANOVA analysis (Figure 19) revealed that
variance between selected answers was statistically significant (p < 0.0001).
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Figure 19. ANOVA results, response choice mean, and standard deviation for
each response group from survey question 20 data. 7+: 7 or more day increase
in sickness duration; 4-6+: 4 to 6 day increase in sickness duration; 1-3+: 1 to 3 day
increase in sickness duration; NC: no change; 1-3-: 1 to 3 day decrease in sickness
duration; 4-6-: 4 to 6 day decrease in sickness duration; 7-: 7 or more day decrease
in sickness duration.
Sixty two percent of those surveyed report no noticeable change. Nearly 17%
of those surveyed said that their average sickness duration has decreased by 1 to 3
days. These results support that GH therapy could accelerate adaptive immune
response in some GHD patients.
Further Interpretation of Miscellaneous Findings:
There is evidence to support that GH may regulate cardiac, integumentary,
thermoregulation, healing, and immune system functions. Survey results on cardiac
function do not support that GH effects cardiac function, but more objective studies
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estimate that GHD patients are at a higher risk of having a heart attack. Survey
results also support that GH treatment could improve wound healing and immune
function in GHD patients. Results of literary analyses support that GH might be a
possible treatment to improve wound healing and boost immune system function in
normal patients. GHD patients could also have integumentary ailments, but findings
oppose that GH therapy can attenuate these side effects. Survey results also
support that GH therapy does not improve thermoregulation. GH has been shown to
increase while normal individuals are exercising. GHD patients only receive GH
once in the evening. These results suggest that GH therapy may need to be altered.
It is hypothesized that a GH pump similar to insulin pumps could attenuate these
currently unaltered integumentary and thermoregulation impairments because it
would mimic the natural pulsatile and physical state dependent secretions of GH in
normal patients. More research is needed to support this hypothesis. Regardless,
results from the survey and literary analysis of recent findings support that GH could
be necessary to maintain healthy cardiac, integumentary, recovery, and immune
system functions.
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Chapter 4: Conclusion
There is evidence to support that GH regulates many more functions than
bone elongation. This thesis has discussed both the analysis of its survey and recent
study results that evaluate these additional roles. Previously mentioned data
supports that GH could regulate energy, metabolism, physical capacity, mental
health, sleep, cognition, cardiovascular health, the integumentary system,
thermoregulation, wound regeneration, and immune system function. Findings
suggest that GH is much more important to the body than was once thought.
Recent findings and analysis of the survey conducted for this thesis support
that GH treatment could be necessary for GHD patients to live a long and healthy
life. Without GH these patients could have mental health conditions, low energy
levels, obesity, impaired immune system function, impaired cardiovascular system
function, impaired exercise ability, cognitive impairment, dysfunctional sleep, and
heat sensitivity. Each of these factors would greatly diminish the quality of the
patient’s life and could shorten the length of their life. There is strong evidence to
support that GH therapy is a necessity for GHD patients of any age. These findings
also suggest that clinicians may need to rethink how they treat GHD patients. One
dose a day may not be enough to attenuate all of the aforementioned side effects. In
the future, patients might take small dosages of GH when they go to bed, when they
are fasting, and when they intend to exercise for a long period. GH is not only
secreted to increase bone elongation, so the cessation of bone elongation does not
support that GH treatment should cease in adult GHD patients.
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The discovery of the effects of GH might also improve the lives of normal
individuals. GH has been observed to improve immune system function in rats with
cancer, to improve wound healing in pigs, to improve some types of bone repair in
humans, to improve cognitive function in a patient with a severe traumatic brain
injury, and to minimize stroke damage in mice. These results support that GH could
be a possible treatment to boost immune system function, accelerate healing, and
repair damage that current medicines cannot treat. GH may be used as a treatment
for these impairments in the coming decade. Though clinical trials of larger samples
will truly determine if GH is a safe treatment for the aforementioned conditions.
It should now be apparent that growth hormone affects much more than
growth. What should be researched next is how GH treatment can improve the lives
of individuals without GHD.
Limitations:
There are limitations of the survey conducted for this thesis. The survey had a
low number (86) of respondents, so results should not be used as proof of the
effects of GH on all individuals with GHD. The sample of subjects includes mostly
Caucasian women. Results thus do not properly represent all GHD patients. Patients
were asked to report how they felt about their symptoms. These feelings may not
translate into objective results if tested further. Patients could have lied. It is also
possible that the cost of GH may have incentivized the patients to feel that GH has
had a positive effect on their symptoms.
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Appendix A:

Figure 20. Prevalence of responses chosen for survey question 1.

Figure 21. Prevalence of responses chosen for survey question 2.
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Figure 22. Prevalence of responses chosen for survey question 3.

Figure 23. Prevalence of responses chosen for survey question 4.
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Figure 24. Prevalence of responses chosen for survey question 5.

Figure 25. Prevalence of responses chosen for survey question 6.
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Figure 26. Prevalence of responses chosen for survey question 7.
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Appendix B:

Figure 27. Prevalence of responses chosen for survey question 8.

Figure 28. Prevalence of responses chosen for survey question 9.
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Figure 29. Prevalence of responses chosen for survey question 10.

Figure 30. Prevalence of responses chosen for survey question 11.
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Figure 31. Prevalence of responses chosen for survey question 12.
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Appendix C:

Figure 32. Prevalence of responses chosen for survey question 13.

Figure 33. Prevalence of responses chosen for survey question 14.
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Figure 34. Prevalence of responses chosen for survey question 15.

Figure 35. Prevalence of responses chosen for survey question 16.
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Figure 36. Prevalence of responses chosen for survey question 17.

Figure 37. Prevalence of responses chosen for survey question 18.
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Figure 38. Prevalence of responses chosen for survey question 19.

Figure 39. Prevalence of responses chosen for survey question 20.

Hutchins 82
References
Akaltun, İ., Çayır, A., Kara, T., & Ayaydın, H. (2018). Is growth hormone deficiency
associated with anxiety disorder and depressive symptoms in children and
adolescents?: A case-control study. Growth Hormone & IGF Research, 41, 2327. doi:10.1016/j.ghir.2018.06.001
Alonzo, Frances. “Highest Educational Levels Reached by Adults in the U.S. Since
1940.” The United States Census Bureau, The United States Census Bureau, 19
Jan. 2018, www.census.gov/newsroom/press-releases/2017/cb17-51.html.
Anderson, L. J., Tamayose, J. M., & Garcia, J. M. (2018). Use of growth hormone, IGFI, and insulin for anabolic purpose: Pharmacological basis, methods of detection,
and adverse effects. Molecular and Cellular Endocrinology, 464, 65-74.
doi:10.1016/j.mce.2017.06.010
Arcopinto, Michele et al. “Growth Hormone Deficiency Is Associated with Worse Cardiac
Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights
from the T.O.S.CA. GHD Study” PloS one vol. 12,1 e0170058. 17 Jan. 2017,
doi:10.1371/journal.pone.0170058
Arwert, L. I., Deijen, J. B., Müller, M., & Drent, M. L. (2005). Long-term growth hormone
treatment preserves GH-induced memory and mood improvements: A 10-year
follow-up study in GH-deficient adult men. Hormones and Behavior, 47(3), 343349. doi:10.1016/j.yhbeh.2004.11.015
Attanasio, F. A., Peter C. Bates, Ken K. Y. Ho, Susan M. Webb, Richard J. Ross,
Christian J. Strasburger, Roger Bouillon, Brenda Crowe, Keith Selander,
Domenico Valle, Steven W. J. Lamberts; Human Growth Hormone Replacement
in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and
Lipid Status—3-Year Results from the HypoCCS Database, The Journal of
Clinical Endocrinology & Metabolism, Volume 87, Issue 4, 1 April 2002, Pages
1600–1606, https://doi.org/10.1210/jcem.87.4.8429
Baquedano, E., Chowen, J., Argente, J., & Frago, L. (2013). Differential effects of GH
and GH-releasing peptide-6 on astrocytes, Journal of Endocrinology, 218(3),
263-274. Retrieved Dec 4, 2018, from
https://joe.bioscientifica.com/view/journals/joe/218/3/263.xml
Barro, Robert J. & Lee, Jong Wha, 2013. "A new data set of educational attainment in
the world, 1950-2010," Journal of Development Economics, Elsevier, vol. 104(C),
pages 184-198.
Basu, A., McFarlane, H. G., & Kopchick, J. J. (2017). Spatial learning and memory in
male mice with altered growth hormone action. Hormones and Behavior, 93, 1830. doi:10.1016/j.yhbeh.2017.04.001
Berberoğlu, M., Sıklar, Z., Darendeliler, F., Poyrazoğlu, S., Darcan, S., Işgüven, P.,
Bideci, A., Ocal, G., Bundak, R., Yüksel, B., … Arslanoğlu, I. (2008). Evaluation
of permanent growth hormone deficiency (GHD) in young adults with childhood

Hutchins 83
onset GHD: a multicenter study. Journal of clinical research in pediatric
endocrinology, 1(1), 30-7.
Bergan-Roller, H. E., & Sheridan, M. A. (2017). The growth hormone signaling system:
Insights into coordinating the anabolic and catabolic actions of growth hormone.
General And Comparative Endocrinology, doi:10.1016/j.ygcen.2017.07.028
Birzniece, V., Nelson, A. E., & Ho, K. K. Y. (2011). Growth hormone and physical
performance. Trends in Endocrinology & Metabolism, 22(5), 171-178.
doi:10.1016/j.tem.2011.02.005
Birzniece, Vita, Anne E. Nelson, and Ken K. Y. Ho. "Growth Hormone and Physical
Performance." Trends in Endocrinology & Metabolism, vol. 22, no. 5, 2011, pp.
171-178
Brod, M., Pohlman, B., Højbjerre, L., Adalsteinsson, J. E., & Rasmussen, M. H. (2014).
Impact of adult growth hormone deficiency on daily functioning and well-being.
BMC research notes, 7, 813. doi:10.1186/1756-0500-7-813
C. Diamond, Marian & B. Scheibel, Arnold & Murphy, G.M. & Harvey, Thomas. (1985).
On the brain of a scientist: Albert Einstein. Experimental neurology. 88. 198-204.
10.1016/0014-4886(85)90123-2.
Caicedo, D., Díaz, O., Devesa, P., & Devesa, J. (2018). Growth hormone (GH) and
cardiovascular system. International Journal of Molecular Sciences, 19(1), 290.
doi:10.3390/ijms19010290
Camilla M. Hoyos, Roo Killick, Daniel M. Keenan, Robert C. Baxter, Johannes D.
Veldhuis, Peter Y. Liu; Continuous Positive Airway Pressure Increases Pulsatile
Growth Hormone Secretion and Circulating Insulin-like Growth Factor-1 in a
Time-Dependent Manner in Men With Obstructive Sleep Apnea: A Randomized
Sham-Controlled Study, Sleep, Volume 37, Issue 4, 1 April 2014, Pages 733–
741, https://doi.org/10.5665/sleep.3580
Chaplin, J. E., Kriström, B., Jonsson, B., Tuvemo, T., Albertsson-Wikland, K.,
Medicinska fakulteten, . . . Umeå universitet. (2015). Growth hormone treatment
improves cognitive function in short children with growth hormone deficiency.
Hormone Research in Paediatrics, 83(6), 390-399. doi:10.1159/000375529
Copinschi, Georges et al. “Sleep disturbances, daytime sleepiness, and quality of life in
adults with growth hormone deficiency” Journal of clinical endocrinology and
metabolism vol. 95,5 (2010): 2195-202.
Darendeliler F, Karagiannis G, Wilton P: Headache, Idiopathic Intracranial Hypertension
and Slipped Capital Femoral Epiphysis during Growth Hormone Treatment: A
Safety Update from the KIGS Database. Horm Res 2007;68(suppl 5):41-47. doi:
10.1159/000110474
Deijen, J. B., Arwert, L. I., & nt, M. L. (2011). The GH/IGF-I axis and cognitive changes
across a 4-year period in healthy adults. ISRN Endocrinology, 2011, 249421-6.
doi:10.5402/2011/249421

Hutchins 84
Devesa, J., Díaz-Getino, G., Rey, P., García-Cancela, J., Loures, I., Nogueiras, S., . . .
Devesa, P. (2015). Brain recovery after a plane crash: Treatment with growth
hormone (GH) and neurorehabilitation: A case report. International Journal of
Molecular Sciences, 16(12), 30470-30482. doi:10.3390/ijms161226244
Devesa, J., Lema, H., Zas, E., Munín, B., Taboada, P., & Devesa, P. (2016). Learning
and Memory Recoveries in a Young Girl Treated with Growth Hormone and
Neurorehabilitation. Journal of clinical medicine, 5(2), 14.
doi:10.3390/jcm5020014
Devesa, P., Gelabert, M., Gonźlez‑Mosquera, T., Gallego, R., Luis Relova, J., Devesa,
J., & Arce, V. M. (2012). Growth hormone treatment enhances the functional
recovery of sciatic nerves after transection and repair. Muscle & Nerve, 45(3),
385-392. doi:10.1002/mus.22303
Díez, J. J., Sangiao-Alvarellos, S., & Cordido, F. (2018). Treatment with growth
hormone for adults with growth hormone deficiency syndrome: Benefits and
risks. International Journal of Molecular Sciences, 19(3), 893.
doi:10.3390/ijms19030893
Elbornsson, M., Horvath, A., Götherström, G., Bengtsson, B., Johannsson, G., &
Svensson, J. (2017). Seven years of growth hormone (GH) replacement
improves quality of life in hypopituitary patients with adult-onset GH deficiency,
European Journal of Endocrinology, 176(2), 99-109.
Falleti, Marina G., et al. "The Effects of Growth Hormone (GH) Deficiency and GH
Replacement on Cognitive Performance in Adults: A Meta-Analysis of the
Current Literature."Psychoneuroendocrinology, vol. 31, no. 6, 2006, pp. 681-691.
Gabrielpillai, Jennis & Geißler, Christin & Stock, Belinda & Stöver, Timo & Diensthuber,
Marc. (2018). Growth hormone promotes neurite growth of spiral ganglion
neurons. NeuroReport. 29. 1. 10.1097/WNR.0000000000001011.
Galy, Olivier, et al. "Sequential Exercise in Triathletes: Variations in GH and Water
Loss."PloS One, vol. 9, no. 4, 2014, pp. e96145.
Gonzalez, Susana, et al. "Effects of Growth Hormone Replacement on Peripheral
Muscle and Exercise Capacity in Severe Growth Hormone Deficiency." Frontiers
in Endocrinology, vol. 9, 2018, pp. 56.
Grönbladh, A., Johansson, J., Nöstl, A., Nyberg, F., & Hallberg, M. (2013). GH improves
spatial memory and reverses certain anabolic androgenic steroid-induced effects
in intact rats, Journal of Endocrinology, 216(1), 31-41. Retrieved Dec 5, 2018,
from https://joe.bioscientifica.com/view/journals/joe/216/1/31.xml
Halperin, J. M., Newcorn, J. H., McKay, K. E., Siever, L. J., & Sharma, V. (2003).
Growth hormone response to guanfacine in boys with attention deficit
hyperactivity disorder: A preliminary study. Journal of Child and Adolescent
Psychopharmacology, 13(3), 283-294. doi:10.1089/104454603322572615

Hutchins 85
Hattori, N. (2008;2009;). Expression, regulation and biological actions of growth
hormone (GH) and ghrelin in the immune system. Growth Hormone and IGF
Research, 19(3), 187-197. doi:10.1016/j.ghir.2008.12.001
Hua, K., Forbes, M. E., Lichtenwalner, R. J., Sonntag, W. E., & Riddle, D. R. (2009).
Adult-onset deficiency in growth hormone and insulin-like growth factor-I alters
oligodendrocyte turnover in the corpus callosum. Glia, 57(10), 1062-1071.
doi:10.1002/glia.20829
Hwa Kim, Suk & Eun, Ju & Heo, Bs & Sang, Woo & , Lee. (2015). The Effect of
Topically Applied Recombinant Human Growth Hormone on Wound Healing in
Pigs. Wounds : a compendium of clinical research and practice. 21.
"Intelligence." Merriam-Webster.com. Merriam-Webster, 2019.
Isgaard, J., Arcopinto, M., Karason, K. et al. Endocrine (2015) 48: 25.
https://doi.org/10.1007/s12020-014-0327-6
Juul A, Hjortskov N, Jepsen LT, Nielsen B, Halkjaer-Kristensen J, Vahl N, Jørgensen
JO, Christiansen JS, Skakkebaek NE. Growth hormone deficiency and
hyperthermia during exercise: a controlled study of sixteen GH-deficient patients.
JCEM. 1995 Nov;80(11):3335-40. https://doi.org/10.1210/jcem.80.11.7593447
Kaltschmidt, Barbara, and Christian Kaltschmidt. "NF-KappaB in Long-Term Memory
and Structural Plasticity in the Adult Mammalian Brain." Frontiers in Molecular
Neuroscience, vol. 8, 2015, pp. 69.
Gantenbein, C., Kogia, C., Abdel-Naser, M.B. et al. Rev Endocr Metab Disord (2016)
17: 259. https://doi.org/10.1007/s11154-016-9378-8
Kumar, P.A., Chitra, P.S., Lu, C. et al. Growth hormone (GH) differentially regulates NFkB activity in preadipocytes and macrophages: implications for GH’s role in
adipose tissue homeostasis in obesity, J Physiol Biochem (2014) 70: 433.
https://doi.org/10.1007/s13105-014-0321-8
Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, et al. Systematic Review:
The Effects of Growth Hormone on Athletic Performance. Ann Intern Med.
;148:747–758. doi: 10.7326/0003-4819-148-10-200805200-00215
Liu, X., Green, K. J., Ford, Z. K., Queme, L. F., Lu, P., Ross, J. L., Lee, F. B., Shank, A.
T., Hudgins, R. C., … Jankowski, M. P. (2017). Growth hormone regulates the
sensitization of developing peripheral nociceptors during cutaneous
inflammation. Pain, 158(2), 333-346.
Liu, Zhihai, et al. "Growth Hormone Increases Lung NF-kappaB Activation and Lung
Microvascular Injury Induced by Lipopolysaccharide in Rats." Annals of Clinical
and Laboratory Science, vol. 32, no. 2, 2002, pp. 164.
Lourenço, J., & Bacci, A. (2017). Human-specific cortical synaptic connections and their
plasticity: Is that what makes us human? PLoS Biology, 15(1), e2001378.
doi:10.1371/journal.pbio.2001378

Hutchins 86
Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 8: Atypical Neurotransmitters". In
Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical
Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 199, 211–221.
ISBN 9780071481274
Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 8: Atypical Neurotransmitters". In
Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical
Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 199, 211–221.
ISBN 9780071481274
Maria, Dos S. R., et al. "Modulation of Macrophage Function by Growth Hormone."
Frontiers in Immunology, vol. 4, 2013.
Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the
immune system. Pediatr Endocrinol Rev 2004 Aug;1(Suppl 3):490-5.
"Memory." Merriam-Webster.com. Merriam-Webster, 2019.
Merlo, E., Freudenthal, R., Maldonado, H., & Romano, A. (2005). Activation of the
transcription factor NF-κB by retrieval is required for long-term memory
reconsolidation.Learning & Memory, 12(1), 23-29. doi:10.1101/lm.82705
Merlo, Emiliano et al. “Activation of the transcription factor NF-kappaB by retrieval is
required for long-term memory reconsolidation” Learning & memory (Cold Spring
Harbor, N.Y.) vol. 12,1 (2005): 23-9.
Molina, D. P., Ariwodola, O. J., Linville, C., Sonntag, W. E., Weiner, J. L., BrunsoBechtold, J. K., & Adams, M. M. (2012). Growth hormone modulates
hippocampal excitatory synaptic transmission and plasticity in old rats.
Neurobiology of Aging, 33(9), 1938-1949.
doi:10.1016/j.neurobiolaging.2011.09.014
Morselli, Lisa L, Arlet Nedeltcheva, Rachel Leproult, Karine Spiegel, Enio Martino, JeanJacques Legros, Roy E Weiss, Jean Mockel, Eve Van Cauter, and Georges
Copinschi. "Impact of GH replacement therapy on sleep in adult patients with GH
deficiency of pituitary origin". European Journal of Endocrinology 168.5 (2013):
763-770. < https://doi.org/10.1530/EJE-12-1037>. Web. 19 Mar. 2019.
N Dubick, Marc & H Ravin, Thomas & Michel, Yvonne & Morrisette, David. (2015). Use
of localized human growth hormone and testosterone injections in addition to
manual therapy and exercise for lower back pain: A case series with 12-month
follow-up. Journal of pain research. 8. 295-302. 10.2147/JPR.S81078.
Niels Møller, Jens Otto Lunde Jørgensen; Effects of Growth Hormone on Glucose,
Lipid, and Protein Metabolism in Human Subjects, Endocrine Reviews, Volume
30, Issue 2, 1 April 2009, Pages 152–177, https://doi.org/10.1210/er.2008-0027
Nyberg, F., Hallberg, M., Medicinska och farmaceutiska vetenskapsområdet,
Institutionen för farmaceutisk biovetenskap, Uppsala universitet, &
Farmaceutiska fakulteten. (2013). Growth hormone and cognitive function.
Nature Reviews. Endocrinology, 9(6), 357-365. doi:10.1038/nrendo.2013.78

Hutchins 87
Ong LK, Chow WZ, TeBay C, Kluge M, Pietrogrande G, Zalewska K, Crock P, Åberg
ND, Bivard A, Johnson SJ, et al. Growth Hormone Improves Cognitive Function
After Experimental Stroke. Stroke. 2018 May;49(5):1257-1266. doi:
10.1161/STROKEAHA.117.020557. Epub 2018 Apr 10. PubMed PMID:
29636425.opiod
Peker, Y. , Svensson, J. , Hedner, J. , Grote, L. and Johannsson, G. (2006), Sleep
apnoea and quality of life in growth hormone (GH)‑deficient adults before and
after 6 months of GH replacement therapy. Clinical Endocrinology, 65: 98-105.
doi:10.1111/j.1365-2265.2006.02555.x
Peterfi, Zoltan et al. “Growth hormone-releasing hormone activates sleep regulatory
neurons of the rat preoptic hypothalamus” American journal of physiology.
Regulatory, integrative and comparative physiology vol. 298,1 (2009): R147-56.
Quik, E. H., Conemans, E. B., Valk, G. D., Kenemans, J. L., Koppeschaar, H. P. F., &
van Dam, P. S. (2012). Cognitive performance in older males is associated with
growth hormone secretion. Neurobiology of Aging, 33(3), 582-587.
doi:10.1016/j.neurobiolaging.2010.03.022
Raschke, Michael, Michael Højby Rasmussen, Shunmugam Govender, David Segal,
Mette Suntum, and Jens Sandahl Christiansen. "Effects of growth hormone in
patients with tibial fracture: a randomised, double-blind, placebo-controlled
clinical trial". European Journal of Endocrinology eur j endocrinol 156.3: 341-351.
< https://doi.org/10.1530/EJE-06-0598>. Web. 20 Mar. 2019.
Renehan, Andrew G., PhD, FRCS, & Brennan, Bernadette M., MD, FRCPCH. (2008).
Acromegaly, growth hormone and cancer risk. Best Practice & Research: Clinical
Endocrinology & Metabolism, 22(4), 639-657. doi:10.1016/j.beem.2008.08.011
Rhodin, A et al. “Recombinant human growth hormone improves cognitive capacity in a
pain patient exposed to chronic opioids” Acta anaesthesiologica Scandinavica
vol. 58,6 (2014): 759-65.
Romijn JA. Pituitary diseases and sleep disorders. Current Opinion in Endocrinology,
Diabetes, and Obesity. 2016 Aug;23(4):345-51. doi:
10.1097/MED.0000000000000265. Review. DOI:
10.1097/MED.0000000000000265
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